63329-46-4

Upstream product

• 118-92-3 anthranilic acid 
• 7697-27-0 2-bromo-4-methylbenzoic acid 
• 584-08-7 potassium carbonate 

Downstream Products

• 86611-52-1 9-(4-Methanesulfonylamino-2-methoxy-phenylamino)-6-methyl-acridine-4-carboxylic acid carbamoylmethyl-amide 
• 78847-71-9 9-(4-Methanesulfonylamino-2-methoxy-phenylamino)-6-methyl-acridine-4-carboxylic acid methylamide 
• 86611-51-0 9-(4-Methanesulfonylamino-2-methoxy-phenylamino)-6-methyl-acridine-4-carboxylic acid amide 
• 86611-50-9 9-(4-Methanesulfonylamino-2-methoxy-phenylamino)-6-methyl-acridine-4-carboxylic acid 4-nitro-phenyl ester; hydrochloride 
• 78847-60-6 9-(4-Methanesulfonylamino-2-methoxy-phenylamino)-6-methyl-acridine-4-carboxylic acid carbamoylmethyl-amide; hydrochloride 
• 78847-69-5 9-Chloro-6-methyl-acridine-4-carboxylic acid 4-nitro-phenyl ester 
• 78847-68-4 p-nitrophenyl 3-methyl-9-oxoacridan-5-carboxylate 

Relevant academic research and scientific papers

3,5-Disubstituted-4'-(9-acridinylamino)-methane-sulfon-m-anisidide compounds having antitumor properties

3,5-Disubstituted-4'-(9-acridinylamino)-methane-sulfon-m-anisidide compounds represented by the general formula STR1 in which R2 and R3 represent, respectively, --CH3 and --CONHCH3, --CH3 and --CONHCH2 CONH2, --Cl and --CONHCH2 CONH2, --CONHCH3 and --CH3 ; and acid addition salts thereof have unexpectedly high antitumor activity in leukemic animals and low or no direct mutagenicity.

Potential antitumor agents. 38. 3-Substituted 5-carboxamido derivatives of amsacrine

The synthesis and biological evaluation of a series of 3-substituted 5-carboxamido derivatives of amsacrine (m-AMSA) are described. This series was developed as the result of previous quantitative structure-activity relationship (QSAR) studies of the antitumor activity of 9-anilinoacridine derivatives. In agreement with these studies, this class of compounds, possessing a variety of small nonpolar groups at the 3-position, together with very hydrophilic carboxamido groups at the 5-position, have high in vivo activity against animal leukemia models.